Literature DB >> 10438922

Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.

J Wild1, M J Grusby, R Schirmbeck, J Reimann.   

Abstract

MHC-I (Ld)-restricted, S28-39-specific CTL responses are efficiently primed in H-2d BALB/c mice injected with low doses of native hepatitis B surface Ag (HBsAg) lipoprotein particles without adjuvants. Priming of this CTL response by exogenous HBsAg required CD4+ T cell "help" and IL-12: this CTL response could be neither induced in mice depleted of CD4+ T cells by in vivo Ab treatment, nor in (CD4+ T cell-competent or CD4+ T cell-depleted) IL-12-unresponsive STAT4-/- knockout BALB/c mice. Codelivery of oligonucleotides (ODN) with immunostimulating CpG sequences (ISS) with exogenous HBsAg reconstituted the CTL response to exogenous HBsAg in CD4+ T cell-depleted normal mice and in CD4+ T cell-competent and CD4+ T cell-depleted STAT4-/- BALB/c mice. Injection (by different routes) of "naked" pCI/S plasmid DNA encoding HBsAg into IL-12-responsive or -unresponsive BALB/c mice efficiently primed the MHC-I-restricted, HBsAg-specific CTL response. CTL priming was not detectable when CD4+ T cell-depleted animals were subjected to genetic immunization. In vivo priming of the well-characterized CD8+ CTL response to HBsAg in "high responder" BALB/c mice either by exogenous surface lipoprotein particles or by DNA vaccination is thus CD4+ T cell dependent. CTL priming by exogenous HBsAg, but not by genetic immunization, is IL-12 dependent. The dependence of CTL priming by exogenous HBsAg on CD4+ T cells can be overcome by codelivering ODN with ISS motifs, and this "adjuvants effect" operates efficiently in IL-12-unresponsive mice. The data characterize a feature of the adjuvant effect of ISS-containing ODN on CTL priming that may be of major interest for the design of CTL-stimulating vaccines with efficacy in immunodeficiency conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438922

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes.

Authors:  Malgorzata Gierynska; Uday Kumaraguru; Seong-Kug Eo; Sujin Lee; Arthur Krieg; Barry T Rouse
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

2.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

3.  Interferon gamma licensing of human dendritic cells in T-helper-independent CD8+ alloimmunity.

Authors:  Roxane Lemoine; Florence Velge-Roussel; Florence Herr; Romain Felix; Hubert Nivet; Yvon Lebranchu; Christophe Baron
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

Review 4.  Induction of antigen cross-presentation by Toll-like receptors.

Authors:  Sandip K Datta; Eyal Raz
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

5.  Different sources of "help" facilitate the antibody response to hepatitis D virus delta antigen.

Authors:  Peter Seizer; Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2004-11-10       Impact factor: 4.599

6.  Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.

Authors:  Wai-Ping Woo; Tracy Doan; Karen A Herd; Hans-Jürgen Netter; Robert W Tindle
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B.

Authors:  Fen-Yu Ren; Hai Jin; Xi-Xu Piao; Feng-Shun Piao
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

8.  Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.

Authors:  Bassel Akache; Felicity C Stark; Yimei Jia; Lise Deschatelets; Renu Dudani; Blair A Harrison; Gerard Agbayani; Dean Williams; Mohammad P Jamshidi; Lakshmi Krishnan; Michael J McCluskie
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.